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Abstract 
Background: The assessment of patients presenting with angina using invasive angiography 
alone is imperfect. By contrast, fractional flow reserve (FFR) allows for assessment of lesion-
specific ischaemia, which is predictive of clinical outcome.  A series of studies has 
demonstrated that the availability of FFR data at the time of diagnostic angiography leads to 
significant differences in the management of those patients.  
Hypothesis: The objective of this paper is to describe assess the consistency in the difference 
in management resulting from an FFR-directed versus and angiogram-directed strategy in 
appropriate observational and randomised trials. 
Methods: A methodical search was made using MEDLINE, Current Contents Connect, 
Google Scholar, EMBASE, Cochrane library, PubMed, Science Direct, and Web of Science. 
Results: Eight studies were identified using the eligibility criteria. A total of 2468 patients 
were recommended to have optimal medical therapy (OMT) alone after initial angiographic 
assessment but, after FFR results were available, a total of 716 (29.0%) were referred for 
revascularisation (PCI 626 patients (25.36%); CABG 90 patients (3.64%)). Similarly, 3766 
patients were originally committed to PCI after initial angiography: of these 1454 patients 
(38.61%) were reconsidered to be suitable for OMT alone and 71 individuals (1.8%) were 
deemed suitable for CABG after FFR data were available. Further, of 366 patients referred 
for CABG based on angiographic data, the availability of FFR data changed the final decision 
to OMT alone in 65 patients (17.76%) and PCI in 51 patients (13.9%). Overall, the 
angiogram-derived management was changed in 22-48% of these study populations when 
FFR data were available. 
Conclusions: Some use of FFR during coronary angiography alters the angiogram-directed 
management in a remarkably consistent manner. These data suggest that routine use of FFR 
at the diagnostic angiogram would improve patient care.  
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Introduction 
It is now well established that assessment of patients presenting with cardiac-sounding chest 
pain based upon angiography alone is flawed.(1, 2) Specifically, the coronary anatomy at 
angiography does not inevitably reflect the presence and extent of myocardial ischaemia, 
which is recognised as the best indicator of the cause of symptoms and near term prognosis, 
and thus represents the clearest target for revascularisation.(1) This is due to a discrepancy 
between the anatomical assessment of lesion severity and the presence or absence of lesion-
level ischaemia.(3) Lesion-level ischaemia is measured by pressure wire assessment using 
fractional flow reserve (FFR). The ability of FFR measurement to predict clinical outcome 
has been established in a variety of randomised clinical trials.  In the deferral of percutaneous 
coronary intervention (DEFER) study, the practice of deferring percutaneous coronary 
intervention (PCI) in lesions that had been identified as requiring PCI based upon 
angiographic appearances, but were FFR negative, was shown to be safe and associated with 
a better clinical outcome than stenting them.(4, 5) Furthermore, in patients who had been 
listed for multi-vessel PCI, the Fractional Flow Reserve Versus Angiography for Multivessel 
Evaluation (FAME) trial demonstrated a reduced incidence of the combined clinical endpoint 
of death, non-fatal myocardial infarction, and repeat revascularization at 1 year, as well as 
lower cost, in an FFR-directed strategy compared to an angiogram-directed approach, despite 
fewer lesions being stented.(6) Fractional Flow Reserve Guided Percutaneous Coronary 
Intervention Plus Optimal Medical Therapy Versus Optimal Medical Therapy (FAME 2) trial 
subsequently demonstrated a reduced rate of unplanned revascularisation in patients with 
FFR positive lesions who were stented compared to a cohort treated with optimal medical 
therapy alone.(7) 
Despite these robust data, the uptake of FFR in routine clinical practice has been lower than 
expected in patients already being considered for PCI, with rates as low as 6.6% reported in 
large PCI registries.(8) Furthermore, a series of predominantly observational studies has been 
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published that demonstrate the ability of FFR to modify the management of patients who are 
undergoing diagnostic angiography for the investigation of chest pain (ie at an earlier stage in 
their management pathway.(9-16) 
The aim of this paper is to describe the degree to which some use of FFR affects the 
angiography-derived management strategy for patients in these studies. 
Methods 
Eligibility criteria 
Using the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines(17) published studied were recognized that describe the effect of the availability of 
FFR on an angiogram-derived management of patients being investigated for chest pain.  
Search strategy 
A methodical search was made using MEDLINE, Current Contents Connect, Google Scholar, 
EMBASE, Cochrane library, PubMed, Science Direct, and Web of Science to October 2016. 
We used the following search MeSH terms: acute coronary syndrome; angina; coronary 
angiography; fractional flow reserve or pressure wire assessment; decision making; outcome 
assessment.  No language restrictions were made. The references of the included publications 
and relevant review articles were checked for additional relevant studies. 
Study selection and data extraction 
Three reviewers (VN, MM and NC) independently checked all titles and abstracts for studies 
potentially meeting the inclusion criteria. The full reports of these studies were retrieved, and 
we analysed these studies in a qualitative manner in order to describe the number of patients 
involved, clinical setting, effect of FFR on assessment of lesion level significance and effect 
of FFR on angiogram-derived management plan. 
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Quality assessment 
The quality of publications was rated using the Quality Assessment Tool for Case Series 
Studies based on the National Heart, Lung, and Blood Institute (NHLBI).(18)  
Results 
Description of studies included in analysis 
Eight studies have been identified that fit our prespecified criteria. The studies were 
published between 2007-2016 and report data derived from between 200 – 3093 patients 
(Figure 1). Seven of the studies were observational and 1 was randomised.(9-16) Seven were 
derived from invasive angiography and intracoronary FFR measurement and one study is 
based on CT coronary angiography and FFRCT. In 4 studies the patients were elective only, in 
1 study only acute coronary syndrome patients were included and in 3 there was a mixture. 
The angiographic lesion characteristics representing triggers for FFR measurement varied 
(range: >30% up to <90%) between studies, as did the number of vessels targeted (range: 
further assessment of at least one intermediate lesion to FFR of all vessels of a diameter that 
was suitable for PCI). 
Quality assessment in included studies 
Quality Assessment Tool for Case Series Studies(18) was used to gauge the quality of 
evidence and all studies were of good quality. Their detailed evaluation has been tabulated in 
table 2. 
Relationship between FFR measurement and change in management plan 
The availability of some FFR data in these studies resulted in a change in management in 
between 22-48% of patients. In all cases this was due to a discrepancy between the 
anatomical and physiological assessment of lesion-specific significance. In 4 studies, the 
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authors provide data on the number of lesions whose significance was changed once FFR 
data were available, and this ranged from 32-48%.  
Sant'Anna et al(9) reported data through analysis of lesions (ie lesion-level) whilst all other 
studies(9-16) reported outcomes based on patient-level data. Overall outcomes based on 
pooled patient data are described here. A total of 2468 patients were recommended to have 
optimal medical therapy (OMT) alone after initial angiographic assessment but, after FFR 
results were available, 626 patients (25.36%) of them were in fact referred for PCI and 90 
patients (3.64%) for surgical revascularization (CABG). Similarly, 3766 patients were 
originally committed to PCI after initial angiography: of these 1454 patients (38.61%) were 
reconsidered to be suitable for OMT alone and 71 individuals (1.8%) were deemed suitable 
for CABG after FFR data were available. Further, of 366 patients referred for CABG based 
on angiographic data, the availability of FFR data changed the final decision to OMT alone in 
65 patients (17.76%) and PCI in 51 patients (13.9%). Lastly, in patients in whom further 
information/functional test (n=254) was recommended after angiography alone, this was 
deemed unnecessary after FFR data were available, with patients being allocated to OMT 
alone (47.2%), PCI (39.4%) and CABG (13%). The tables 3, 4 and figure 2 illustrate in detail 
the effect on angiography-derived management of FFR data. 
Only 2 studies reported clinical event data, and the effect of FFR data upon the angiogram-
derived outcome.(13, 14) Firstly, in the Fractional flow reserve vs. angiography in guiding 
management to optimize outcomes in non-ST-segment elevation myocardial infarction 
(FAMOUS-NSTEMI) trial, which was randomised, there was no significant difference in 
clinical events in either group.(14) Specifically, 8.0% of patients in the FFR-guided group 
and 8.6% in the angiography-guided group experienced cardiac death, non-fatal myocardial 
infarction or heart failure hospitalization (P = 0.89). Major adverse cardiac events excluding 
MI related to revascularization occurred in 5.7% of patients in the FFR-guided group and 
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2.9% patients in the angiography-guided group (P =0.25). By contrast, the Danish registry 
reported that FFR-guided PCI was associated with a significantly lower rate of MI (49% 
relative risk [RR] reduction P value:0.015), MI-driven TLR (59% RR reduction P 
value:0.045) and 40% RR reduction in the combined endpoint death/MI(P value:0.011) as 
compared to an angiography-guided strategy.(13) Further, a similar degree of effect for the 
FFR-guided strategy on the death/MI endpoint was seen in all of the clinical subgroups 
studied (stratified by age, gender, diabetes, extent of coronary disease, cardiovascular risk 
factors, chronic renal disease). 
Discussion 
This meta-analysis reports the consistency with which the availability of some FFR data at 
the diagnostic angiogram results in a change in the management strategy that is applied to 
patients with chest pain derived from angiographic data alone. Specifically, in between 22-
48% of patients in these study populations there was a change in the recommended 
angiogram-derived strategy.   
The reason for this is a consistent mismatch between the angiographic assessment of lesion 
severity, and therefore “significance” as a potential target for revascularisation, and the 
binary allocation that is derived from FFR measurement (ie FFR positive or negative). 
Recently, several publications(14, 15, 19, 20) have illustrated this important issue. One 
study(20) showed that a diameter stenosis of more than 50% stenosis was not efficient in 
identifying a functionally significant lesion (FFR<0.80) with a sensitivity of 61%, specificity 
of 67% and accuracy of 64%. A detailed analysis from the FAME trial(19) showed that 35% 
of the 50% to 70% stenosis, 80% of the 71% to 90% stenosis and 96% of the 91% to 99% 
stenosis category were functionally significant with a FFR of ≤0.80. Curzen et al(15) had 
comparable results with 53% of >70% stenosis, 33% of 51%-70% stenosis, 33% of 31% and 
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50%, and 13% of 0%-30% stenosis were functionally significant with a FFR of <0.80.  Given 
this consistent discrepancy between the angiographic appearance of individual lesions and 
their physiological “significance”, it is predictable that the management of patients with chest 
pain would be optimised by adoption of FFR measurement in a higher proportion of them at 
the time of their original diagnostic angiogram. 
Measurement of FFR in coronary arteries has been unequivocally shown to be predictive of 
outcome in terms of acute cardiac events and requirement for revascularisation.(3) A series of 
randomised trials has established that FFR measurement allows for symptomatically and 
prognostically beneficial outcome by directing PCI revascularisation at both a patient- and 
lesion-specific level. These trials have, in the process, highlighted the flaws associated with a 
patient pathway based upon angiographic lesion assessment alone. Despite these data, uptake 
of FFR remains limited to a small minority of patients undergoing diagnostic angiography in 
routine clinical practice. For example, in a recent analysis derived from the unselected 
London PCI registry,(8) only 2767 patients out of 64,232 patients who underwent PCI had 
pressure wire assessment (6.6%).   
Given the demonstrable ability of FFR measurement to influence PCI-based revascularisation 
in patients who had previously undergone diagnostic angiography, it is logical to consider the 
potentially wider benefit of applying this concept to patients at the earlier stage in the care 
pathway when the original diagnostic angiogram is being undertaken. Application of FFR 
data at the diagnostic stage has the potential to influence all management outcomes, whether 
based upon OMT or revascularisation, at both patient- and lesion-specific levels. This 
concept has now been explored in several recent studies that include a variety of designs, 
patient groups, and indications for FFR. However, despite this heterogeneity, they report a 
highly consistent effect to modify the angiogram-derived management plan in between 22-
48% of the patients included. 
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The relatively poor uptake of FFR at the stage of diagnostic angiography is explained by 
many factors. These include perceived concerns about cost and safety, reluctance to increase 
the procedure time and complexity, poor education or awareness of the potential advantage to 
patients, reluctance to downgrade candidates for PCI to OMT, the lack of a definitive 
randomised trial testing the hypothesis in patients at diagnostic angiography.     
The health economics of FFR has been assessed in three different healthcare systems namely 
the United States,(21) United Kingdom(22) and Australia.(23) The analysis from the FAME 
trial(21) revealed a significant reduction in mean overall cost 2385 USD (P<0.001) in FFR 
arm compared to the angiographic arm at end of 12 months and this robust result was 
maintained across subgroups. In addition, among 5000 samples a bootstrap simulation 
analysis showed FFR guided strategy to be cost saving in 90.74% and attained cost 
effectiveness at 99.96% (threshold of $50,000/ quality-adjusted life-year gained). A similar 
analysis conducted in the Australian health system demonstrated that the impact of FFR 
guided PCI’s cost effectiveness was substantial with a total cost savings ranging from 1.8 to 
14.5 million AUD over a period of 24 months.(23) However, in the health economic analysis 
of the FAMOUS-NSTEMI trial from the United Kingdom(22) demonstrated a minor increase 
in cost of £112 and an increase in quality-adjusted life years by 0.02. 
Recently, using complex novel computer modelling it has become possible to derive FFR 
from CT coronary angiography, termed FFRCT. This has been tested in a series of diagnostic 
accuracy studies and offers the promise of assessing patients coronary and physiology non-
invasively. One of the studies included in this paper, FFRCT RIPCORD, tested the effect that 
having FFRCT available had on the CT angiogram-derived management plan of 200 
cases.(12) The result was that management changed in 36% of cases, which is entirely 
consistent with the degree of change seen in the exclusively invasive studies included here, 
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and again was clearly due to the discrepancy between the angiographic and physiological 
assessment of the significance of an individual lesion. 
There are a number of limitations of this study. Firstly, the studies described are 
heterogeneous in terms of design, patient demographic and lesions included as triggers for 
FFR measurement. This perhaps makes the consistency of the effect of FFR on management 
all the more convincing. Secondly, only one of the reported studies was randomised, 
although, once again, the results obtained from it are entirely consistent with the other data. 
Third, we cannot report the specific degree in discrepancy between the angiographic and 
lesion assessment in all these studies, because the data are only available in 4 of them. 
The implications of this consistency in the effect of FFR data availability in addition to the 
angiogram alone on patient management are potentially of clinical significance. In 
contemporary front line clinical practice only a minority of patients with chest pain who 
undergo diagnostic angiography are offered FFR assessment at that time. It is likely that a 
substantial proportion (perhaps between 22-48%?) of such patients have a management plan 
made that is suboptimal according to the premise that it is patient- and lesion-level ischaemia 
that represents the dominant target for an outcome benefit relating to revascularisation. 
Further data about the role of FFR as a routine component of the diagnostic angiogram are 
now required from appropriately powered randomised trials such as RIPCORD 2 
(NCT02892903), but even before such trials have reported there is a strong case that FFR 
measurement could, and indeed should, be used to tailor therapy more accurately to the 
benefit of our patients. 
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Name Country Study type Study period Inclusion criteria Exclusion criteria Year 
Sant'Anna et al(9) Brazil Prospective October 2004 
to April 2005 
Elective PCI Transmural acute myocardial infarction (AMI) in 
the 
last 7 days, chronic total occlusion, or 
angiographically significant left main disease 
2007 
Curzen et al The RIPCORD 
Study(15) 
United Kingdom Prospective NA Stable cardiac-sounding CP included 
the presence in any epicardial vessel of ≥2.25 
mm diameter of a 
≥30% stenosis  
Failure to provide written informed consent, 
participation in other clinical studies, previous 
CABG, acute coronary syndrome at presentation, 
diagnostic angiography or PCI within the 
previous 12 months, contraindication to 
adenosine, severe valve disease, serum creatinine 
>180 
μmol/L, and life-threatening comorbidity 
2014 
Nakamura et al, CVIT-DEFER 
Registry(11) 
Japan Prospective December 2012 and 
September 2013 
Angiographically intermediate to moderate 
coronary stenosis and in whom FFR was 
clinically indicated 
NA 2014 
Layland et al, FAMOUS–
NSTEMI trial(14) 
United Kingdom Prospective October 2011 to May 
2013 
NSTEMI and with at least one risk factor for 
coronary artery disease (e.g. diabetes mellitus) 
within 72 h of the index episode of myocardial 
ischaemia or if there 
was a history of recurrent ischaemic symptoms 
within 5 days. ≥1 coronary stenosis ≥30% of 
the lumen diameter assessed visually 
Presence of ischaemic symptoms that 
were not controlled by medical therapy, 
haemodynamic instability, MI with persistent ST 
elevation, intolerance to anti-platelet drugs, 
ineligible for coronary revascularization, a 
treatment plan for non-coronary heart 
surgery (e.g. valve surgery), a history of prior 
CABG, angiographic evidence of severe (e.g. 
diffuse calcification), a life expectancy, 1 year 
and an inability to give informed consent. 
2014 
Van Belle eta l, FFR-R3F 
study(16) 
France Prospective October 2008 to June 
2010 
NA NA 2014 
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Baptista et al,  POST-IT 
Multicenter Registry(10) 
Portugal Prospective March 2012 to 
November 2013 
NA Unwillingness to provide written informed 
consent and life expectancy 
<1 year because of known noncardiovascular 
comorbidity 
2016 
De Backer et al(13) Denmark Prospective 1 July 2010 and 30 
June 2014 
Stable angina pectoris 
(AP) and at least one 50-89% coronary stenosis 
were selected 
NA 2016 
Curzen et al The FFRCT 
RIPCORD Study(12) 
United Kingdom Prospective NA Stable cardiac-sounding CP included 
the presence in any epicardial vessel of ≥2.25 
mm diameter of a 
≥30% stenosis  
Failure to provide written informed consent, 
participation in other clinical studies, previous 
CABG, acute coronary syndrome at presentation, 
diagnostic angiography or PCI within the 
previous 12 months, contraindication to 
adenosine, severe valve disease, serum creatinine 
>180 μmol/L, and life-threatening comorbidity 
2016 
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Name No. Patients % Female Mean Age, 
years 
Follow up 
period 
Setting Diabetes 
mellitus 
% Multivessel 
disease 
Unstable 
angina 
pectoris 
ACS% FFR 
Limit 
Stenosis 
Limit 
Number of 
diameter 
stenosis 
 >70% 
Sant'Anna et al(9) 250 38% 61 NA Elective 23% 70% 7% 0% 0.75 >50% 327 
Curzen et al The 
RIPCORD Study(15) 
200 25% 64 NA Elective  NA NA NA 0 0.8 >30% 68 
Nakamura et al, 
CVIT-DEFER 
Registry(11) 
3093 26.2 69.5 NA Elective & ACS 37.7 34.8 7.2 1.4 0.8 50-90% NA 
Layland et al, 
FAMOUS–NSTEMI 
trial(14) 
350 24.6 62.3 12 months ACS 14.8 29 0 100 0.8 >30% 63.1 
Van Belle eta l, FFR-
R3F study(16) 
1075 24.70% 64.7 12 months Elective & ACS 35.8 47.6 NA 19.5 0.8 35-65% NA 
Baptista et al,  POST-
IT Multicenter 
Registry(10) 
918 23.7 65.1 12 months Elective & ACS 35 37.5 4.4 35.4 0.75-
0.8 
Intermedi
ate 
31.9 
De Backer et al(13) 1,716 28.8 64.5 23.2 
months 
Elective 23.8 32.5 0 0 0.8 50-89% 74 
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Table 1: Clinical characteristics of the publications included in the systematic review 
  
Curzen et al The 
FFRCT RIPCORD 
Study(12) 
200 NA NA  Elective NA NA NA 0 0.8 >70% 126 
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Criteria Sant'Anna 
et al(9) 
Curzen et 
al The 
RIPCORD 
Study(15) 
Nakamura 
et al, CVIT-
DEFER 
Registry(11) 
Layland et 
al, 
FAMOUS–
NSTEMI 
trial(14) 
Belle eta 
l, FFR-
R3F 
study(16) 
Baptista 
et al, 
POST-IT 
study(10) 
Backer 
et 
al(13) 
Curzen et 
al The 
FFRCT 
RIPCORD 
Study(12) 
1. Was the study question or 
objective clearly stated? 
Yes Yes Yes Yes Yes Yes Yes Yes 
2. Was the study population 
clearly and fully described, 
including a case definition? 
Yes Yes Yes Yes Yes Yes Yes Yes 
3. Were the cases consecutive? Yes Yes Yes Yes Yes Yes Yes Yes 
4. Were the subjects 
comparable? 
Yes Yes Yes Yes Yes Yes Yes Yes 
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5. Was the intervention clearly 
described? 
Yes Yes Yes Yes Yes Yes Yes Yes 
6. Were the outcome measures 
clearly defined, valid, reliable, 
and implemented consistently 
across all study participants? 
Yes Yes Yes Yes Yes Yes Yes Yes 
7. Was the length of follow-up 
adequate? 
NA NA NA Yes Yes Yes Yes NA 
8. Were the statistical methods 
well described? 
Yes Yes Yes Yes Yes Yes Yes Yes 
9. Were the results well 
described? 
Yes Yes Yes Yes Yes Yes Yes Yes 
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Quality Rating  Good Good Good Good Good Good Good Good 
 
Table 2: Quality assessment of the studies 
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Table 3: Management decisions after angiography and FFR 
 Results    Angiogr
aphic 
Intention 
   FFR 
Intent
ion 
   Adve
rse 
Event
s 
Addition
al 
contrast 
Addition
al 
screening 
time 
Name Number 
of lesions 
with FFR 
Change 
in 
manage
ment 
Lesio
n 
Chan
ge 
Data 
based 
on  
Medical 
treatmen
t 
Percutaneo
us 
Revasculari
zation 
Surgical 
Revasculari
zation 
Further 
information/fu
nctional test 
Medic
al 
treatm
ent 
Percutaneo
us 
Revasculari
zation 
Surgical 
Revasculari
zation 
Further 
information/fu
nctional test 
   
Sant'Anna et 
al(9) 
452 48% 32% Lesio
ns 
102 350 0 0 158 294 0 0 NA   
Curzen et al 
The 
RIPCORD 
Study(15) 
NA 26% 32% Patie
nts 
72 90 23 15 89 80 30 1 0.02
% 
70 mL 
(interqu
artile 
range, 
140)   
342 
seconds 
(interqua
rtile 
range,52
6) 
Nakamura et 
al, CVIT-
DEFER 
Registry(11) 
3709 39% NA Patie
nts 
1066 1963 64 0 1496 1520 77 0 NA NA NA 
Layland et al, 
FAMOUS–
NSTEMI 
trial(14) 
NA 22% NA Patie
nts 
18 144 14 0 40 125 11 0 NA NA NA 
Van Belle eta 
l, FFR-R3F 
study(16) 
NA 43% NA Patie
nts 
587 409 79 0 619 342 114 0 NA NA NA 
Baptista et al,  
POST-IT 
Multicenter 
1285 44% 45% Patie
nts 
360 319 38 201 438 404 76 0 NA NA NA 
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Registry(10) 
De Backer et 
al(13) 
NA 31% 48% Patie
nts 
298 754 140 0 596 468 128 0 NA NA NA 
Curzen et al 
The FFRCT 
RIPCORD 
Study(12) 
NA 36% NA Patie
nts 
67 87 8 38 113 78 9 0 NA NA NA 
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Table 4: Relationship between FFR measurement and change in management plan 
 Data based on Post FFR management Medical 
treatment 
Percutaneous 
Revascularization 
Surgical 
Revascularization 
Further information 
/functional test 
  Post angiography 
management 
    
Sant'Anna et al(9) Lesions Medical treatment 58 44 0 0 
  Percutaneous 
Revascularization 
100 250 0 0 
  Surgical Revascularization 0 0 0 0 
  Further 
information/functional test 
0 0 0 0 
Curzen et al The 
RIPCORD Study(15) 
Patients Medical treatment 63 6 3 0 
  Percutaneous 
Revascularization 
24 64 2 0 
  Surgical Revascularization 1 3 19 0 
  Further 
information/functional test 
1 7 6 1 
Nakamura et al, CVIT-
DEFER Registry(11) 
Patients Medical treatment 694 350 22 0 
  Percutaneous 
Revascularization 
788 1157 18 0 
  Surgical Revascularization 14 13 37 0 
  Further 
information/functional test 
0 0 0 0 
Layland et al, FAMOUS–
NSTEMI trial(14) 
Patients Medical treatment 13 4 1 0 
  Percutaneous 
Revascularization 
25 117 2 0 
  Surgical Revascularization 2 4 8 0 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
FFR in angiogram-directed management 
Curzen et al  
December 2016 
21 
 
  Further 
information/functional test 
0 0 0 0 
Van Belle eta l, FFR-R3F 
study(16) 
Patients Medical treatment 393 153 41 0 
  Percutaneous 
Revascularization 
196 180 33 0 
  Surgical Revascularization 30 10 39 0 
  Further 
information/functional test 
0 0 0 0 
Baptista et al,  POST-IT 
Multicenter Registry(10) 
Patients Medical treatment 261 83 16 0 
  Percutaneous 
Revascularization 
79 229 11 0 
  Surgical Revascularization 7 9 22 0 
  Further 
information/functional test 
91 83 27 0 
De Backer et al(13) Patients Medical treatment 269 23 6 0 
  Percutaneous 
Revascularization 
316 433 5 0 
  Surgical Revascularization 11 12 117 0 
  Further 
information/functional test 
0 0 0 0 
Curzen et al The FFRCT 
RIPCORD Study(12) 
Patients Medical treatment 59 7 1 0 
  Percutaneous 
Revascularization 
26 61 0 0 
  Surgical Revascularization 0 0 8 0 
  Further 
information/functional test 
28 10 0 0 
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Figure 1 PRISMA Flow Diagram of included publications 
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Figure 2A: Reclassification of management strategy after pressure wire 
assessment subgroup: optimal medical therapy (OMT= optimal medical therapy 
CABG = coronary artery bypass surgery and PCI=percutaneous coronary 
intervention) 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
FFR in angiogram-directed management 
Curzen et al  
December 2016 
28 
 
 
Figure 2B: Reclassification of management strategy after pressure wire 
assessment subgroup: percutaneous coronary intervention (OMT= optimal 
medical therapy CABG = coronary artery bypass surgery and PCI=percutaneous 
coronary intervention) 
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Figure 2C: Reclassification of management strategy after pressure wire 
assessment subgroup: coronary artery bypass surgery (OMT= optimal medical 
therapy CABG = coronary artery bypass surgery and PCI=percutaneous coronary 
intervention) 
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Figure 2D: Reclassification of management strategy after pressure wire 
assessment subgroup: further information/functional test (OMT= optimal medical 
therapy CABG = coronary artery bypass surgery and PCI=percutaneous coronary 
intervention) 
